Immunotech Laboratories, Inc. Announces the Results From Gap Analysis Report
June 19 2013 - 9:05AM
Immunotech Laboratories, Inc. (Pink Sheets:IMMB) today announced
the results from Gap Analysis report.
Immnuotech President Harry Zhabilov and Vice President of
business development Blaine Nabors announced the results from the
Gap Analysis report. This report is the first step in the moving
towards FDA clinical trials for Immunotech Laboratories.
IND Directions' Dr. Patricia Williams has conducted a gap
analysis with the objective of identifying areas that require more
information on IPF for the Pre-IND and IND submissions to FDA. The
materials reviewed included general product technology overviews,
meeting abstract, technical information on the peptide structure
and manufacturing, and a protocol for a pilot clinical trial
conducted in Mexico.
Dr. Williams reports that Zhabilov's IPF platform proposed
mechanism of action represents a novel approach for the treatment
of HIV via inhibition of HIV infection (i.e. blocking attachment
and entry into T-cells) and stimulating cell-mediated
immunity. Additional studies in cell culture and in animals
were recommended to further document IPF's mechanism of action and
efficacy against HIV.
Zhabilov and Mr. Nabors stated that Immunotech Laboratories is
now preparing for the Pre-IND studies that will begin by the end of
this year and be subsequently presented to the FDA. Mr. Nabors
said "We strive to provide further advancements of Immunotech
Inactivated Pepsin Fraction "IPF"
About Immunotech Laboratories
Immunotech Laboratories is a drug development company committed
to the commercialization of its proprietary proteins for the
treatment of debilitating infectious diseases such as HIV and AIDS.
www.immunotechlab.com
Safe Harbor Statement: This news release
contains forward-looking statements that involve risks and
uncertainties associated with financial projections, budgets,
milestone timelines, clinical development, regulatory approvals,
and other risks described by Immunotech Laboratories, Inc. from
time to time in its periodic reports filed with the SEC. IPF is not
approved by the US Food and Drug Administration or by any
comparable regulatory agencies elsewhere in the world. While
Immunotech Laboratories believes that the forward-looking
statements and underlying assumptions contained therein are
reasonable, any of the assumptions could be inaccurate, including,
but not limited to, the ability of Immunotech Laboratories to
establish the efficacy of IPF in the treatment of any disease or
health condition, the development of studies and strategies leading
to commercialization of IPF in the United States, the obtaining of
funding required to carry out the development plan, the completion
of studies and tests on time or at all, and the successful outcome
of such studies or tests. Therefore, there can be no assurance that
the forward-looking statements included in this release will prove
to be accurate. In light of the significant uncertainties inherent
in the forward-looking statements included herein, Immunotech
Laboratories or any other person that the objectives and plans of
Immunotech Laboratories will be achieved should not regard the
forward-looking statements as a representation.
CONTACT: Company Contact:
VP of Business Development
Blaine Nabors : 713-875-9200.
E-mail: naborsgroup@yahoo.com
Immunotech Laborator (CE) (USOTC:IMMB)
Historical Stock Chart
From Jul 2024 to Aug 2024
Immunotech Laborator (CE) (USOTC:IMMB)
Historical Stock Chart
From Aug 2023 to Aug 2024